Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...

The dose is measured in milligrams (mg). Of the two drugs ... risk of heart disease as measured by a cardiac risk calculator. Victoza and Ozempic are two injectable GLP-1 agonists used to treat type 2 ...

Tirzepatide is similar to semaglutide, which is used in medications like Ozempic ... adverse effects after taking a 15-mg dose of tirzepatide. Many families have filed lawsuits against the makers of ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

There is no record of Denmark announcing the tariff on Ozempic exports. The social media user who first shared the claim ...